Lipigon Pharmaceuticals AB (publ) (STO:LPGO)
Sweden · Delayed Price · Currency is SEK 0.0060
+0.0004 (7.14%)
At close: Mar 4, 2026
STO:LPGO Revenue
Lipigon Pharmaceuticals AB had revenue of 1.32M SEK in the twelve months ending September 30, 2025, down -85.32% year-over-year. In the year 2024, Lipigon Pharmaceuticals AB had annual revenue of 10.29M, down -37.30%.
Revenue (ttm)
1.32M
Revenue Growth
-85.32%
P/S Ratio
2.76
Revenue / Employee
188.14K
Employees
7
Market Cap
3.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.29M | -6.12M | -37.30% |
| Dec 31, 2023 | 16.41M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 2.21M | -1.80M | -44.86% |
| Dec 31, 2020 | 4.01M | 2.27M | 130.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nanologica AB | 21.05M |
| Fluicell AB | 15.22M |
| ExpreS2ion Biotech Holding AB | 10.85M |
| AcouSort AB | 10.43M |
| Aptahem AB | 2.59M |
| 2cureX AB | 1.98M |
| NanoEcho AB | 487.00K |
| Novakand Pharma AB | 14.00K |